Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v2-FR
Language French French
Date Updated 2023-01-30 2023-01-05
Drug Identification Number 02082152 02082152
Brand name GENTAMICIN(E) GENTAMICIN(E)
Common or Proper name GENTAMICIN(E) GENTAMICIN(E)
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients GENTAMICIN GENTAMICIN
Strength(s) 1.6MG 1.6MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 50mL (JB0852P) 50mL (JB0852P)
ATC code J01GB J01GB
ATC description AMINOGLYCOSIDE ANTIBACTERIALS AMINOGLYCOSIDE ANTIBACTERIALS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2023-01-09 2023-01-09
Actual start date 2023-01-09 2023-01-09
Estimated end date 2023-02-06 2023-01-30
Actual end date
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments Baxter product Gentamicin Sulfate Injection in 0.9% Sodium Chloride Injection 1 mg / mL (100 mg / 100 mL) (JB0863) is available as a substitute if aligned with clinical practice. Baxter product Gentamicin Sulfate Injection in 0.9% Sodium Chloride Injection 1 mg / mL (100 mg / 100 mL) (JB0863) is available as a substitute if aligned with clinical practice.
Health Canada comments